Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Sells $48,782.16 in Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada sold 38,716 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the transaction, the chief financial officer now directly owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. This trade represents a 43.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Regulus Therapeutics Trading Down 3.1 %

NASDAQ RGLS opened at $1.24 on Friday. Regulus Therapeutics Inc. has a 1-year low of $1.13 and a 1-year high of $3.79. The company has a market capitalization of $81.22 million, a price-to-earnings ratio of -1.16 and a beta of 1.60. The stock’s 50 day moving average is $1.52 and its two-hundred day moving average is $1.58.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

Several large investors have recently made changes to their positions in RGLS. NEA Management Company LLC bought a new position in Regulus Therapeutics during the 3rd quarter valued at about $10,154,000. Point72 Asset Management L.P. bought a new position in shares of Regulus Therapeutics in the third quarter valued at approximately $1,403,000. Bank of New York Mellon Corp acquired a new position in shares of Regulus Therapeutics in the 2nd quarter worth approximately $352,000. The Manufacturers Life Insurance Company bought a new stake in Regulus Therapeutics during the 3rd quarter worth approximately $204,000. Finally, Tyche Wealth Partners LLC increased its holdings in Regulus Therapeutics by 920.6% during the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 95,694 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.